• 검색 결과가 없습니다.

Lobectomy versus Sublobar Resection in Non-Lepidic Small-Sized Non-Small Cell Lung Cancer

N/A
N/A
Protected

Academic year: 2021

Share "Lobectomy versus Sublobar Resection in Non-Lepidic Small-Sized Non-Small Cell Lung Cancer"

Copied!
9
0
0

로드 중.... (전체 텍스트 보기)

전체 글

Loading

수치

Table 1. Clinical characteristics of patients with non-lepidic and lepidic NSCLC who underwent sublobar resection or lobectomy Characteristic Non-lepidic NSCLC Lepidic NSCLC Sublobar  resection (n=60) Lobectomy (n=131) p-value Sublobar  resection (n=50) Lo
Table 2. Pathological characteristics of sublobar resection and lobectomy in non-lepidic NSCLC and lepidic NSCLC
Fig. 1. Five-year recurrence-free survival (A) and 5-year overall survival (B) of non-lepidic NSCLC (sublobar resection versus lobectomy)
Table 3. Univariate and multivariate analysis of factors affect- affect-ing the recurrence of non-lepidic non-small cell lung cancer of  2 cm or less (Cox proportional hazard model)
+2

참조

관련 문서

• Phase II clinical trials of PI3Kδ inhibitor (idelalisib) showed dramatic response in patients with previously treated indolent non-hodgkin’s

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable

Patients with breast cancer; ovarian cancer; renal cell carcinoma; pancreatic neuroendocrine cancer; colorectal cancer; head and neck cancer; non-small cell lung

Method We obtained blood samples from 49 patients who underwent surgical treatment for esophageal squamous cell cancer (ESCC) We performed ctDNA analysis with

따라서 본 연구에서는 비흡수성 차단막으로써 사용되고 있는 고가의 고어텍스 소재 의 치과의료용 차단막을 대체하기 위하여

The HbA1c level is correlated with cardiovascular risk factor in non diabetic elderly population and we suggest that HbA1c may predict cardiovascular risk as

In this study, we developed a non-toxic titanium alloy with low elastic modulus in order to improve biocompatibility, and the surface characteristics of

Overall survival in elderly extensive-stage small cell lung cancer patients received no less than four cycles of the first-line chemotherapy according to